Nothing Special   »   [go: up one dir, main page]

WO2005092297A3 - A stable pharmaceutical composition comprising an acid labile drug - Google Patents

A stable pharmaceutical composition comprising an acid labile drug Download PDF

Info

Publication number
WO2005092297A3
WO2005092297A3 PCT/US2005/006589 US2005006589W WO2005092297A3 WO 2005092297 A3 WO2005092297 A3 WO 2005092297A3 US 2005006589 W US2005006589 W US 2005006589W WO 2005092297 A3 WO2005092297 A3 WO 2005092297A3
Authority
WO
WIPO (PCT)
Prior art keywords
acid labile
pharmaceutical composition
labile drug
stable pharmaceutical
provides
Prior art date
Application number
PCT/US2005/006589
Other languages
French (fr)
Other versions
WO2005092297A2 (en
Inventor
Capua Simona Di
Nava Shterman
Limor Ari Pardo
Esther Itach
Original Assignee
Teva Pharma
Capua Simona Di
Nava Shterman
Limor Ari Pardo
Esther Itach
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma, Capua Simona Di, Nava Shterman, Limor Ari Pardo, Esther Itach filed Critical Teva Pharma
Priority to CA002558535A priority Critical patent/CA2558535A1/en
Priority to MXPA06009991A priority patent/MXPA06009991A/en
Priority to JP2007501900A priority patent/JP2007526319A/en
Priority to EP05724184A priority patent/EP1720527A2/en
Publication of WO2005092297A2 publication Critical patent/WO2005092297A2/en
Priority to IL177869A priority patent/IL177869A0/en
Publication of WO2005092297A3 publication Critical patent/WO2005092297A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention provides a stable pharmaceutical composition of an acid labile drug such as a pharmaceutically active substituted benzimidazole compound, comprising: a) an inner core coated with the acid labile drug; b) a first intermediate coating devoid of an alkaline stabilizing agent and the benzimidazole compound; c) a second intermediate coating comprising an alkaline stabilizing agent; and, d) an outer enteric layer. The present invention also provides a method of preparing the same.
PCT/US2005/006589 2004-03-03 2005-03-02 A stable pharmaceutical composition comprising an acid labile drug WO2005092297A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA002558535A CA2558535A1 (en) 2004-03-03 2005-03-02 A stable pharmaceutical composition comprising an acid labile drug
MXPA06009991A MXPA06009991A (en) 2004-03-03 2005-03-02 A stable pharmaceutical composition comprising an acid labile drug.
JP2007501900A JP2007526319A (en) 2004-03-03 2005-03-02 Stable pharmaceutical composition comprising an acid labile drug
EP05724184A EP1720527A2 (en) 2004-03-03 2005-03-02 A stable pharmaceutical composition comprising an acid labile drug
IL177869A IL177869A0 (en) 2004-03-03 2006-09-03 A stable pharmaceutical composition comprising an acid labile drug

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54965304P 2004-03-03 2004-03-03
US60/549,653 2004-03-03

Publications (2)

Publication Number Publication Date
WO2005092297A2 WO2005092297A2 (en) 2005-10-06
WO2005092297A3 true WO2005092297A3 (en) 2006-10-12

Family

ID=34961526

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/006589 WO2005092297A2 (en) 2004-03-03 2005-03-02 A stable pharmaceutical composition comprising an acid labile drug

Country Status (8)

Country Link
US (2) US20050214372A1 (en)
EP (1) EP1720527A2 (en)
JP (1) JP2007526319A (en)
CN (1) CN1964704A (en)
CA (1) CA2558535A1 (en)
IL (1) IL177869A0 (en)
MX (1) MXPA06009991A (en)
WO (1) WO2005092297A2 (en)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050163846A1 (en) * 2001-11-21 2005-07-28 Eisai Co., Ltd. Preparation composition containing acid-unstable physiologically active compound, and process for producing same
AU2004233846B2 (en) 2003-04-29 2010-07-01 Nalpropion Pharmaceuticals Llc Compositions for affecting weight loss
JPWO2005092336A1 (en) * 2004-03-26 2008-02-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 Dissolution control preparation and production method thereof
US20060024362A1 (en) * 2004-07-29 2006-02-02 Pawan Seth Composition comprising a benzimidazole and process for its manufacture
WO2007037259A1 (en) * 2005-09-29 2007-04-05 Eisai R & D Management Co., Ltd. Pulse preparation having improved disintegration properties in vivo
EP1785135A1 (en) * 2005-11-10 2007-05-16 Laboratorios Del Dr. Esteve, S.A. New stabilized galenic formulations comprising lansoprazole and their preparation
EP3132792B1 (en) 2005-11-22 2019-09-11 Nalpropion Pharmaceuticals, Inc. Composition and methods for increasing insulin sensitivity
ES2383330T3 (en) * 2005-11-28 2012-06-20 Orexigen Therapeutics, Inc. Zonisamide Sustained Release Formulation
CA2633825A1 (en) * 2005-12-20 2007-07-05 Teva Pharmaceutical Industries Ltd. Lansoprazole orally disintegrating tablets
WO2007078271A2 (en) * 2005-12-20 2007-07-12 Teva Pharmaceutical Industries Ltd. Lansoprazole orally disintegrating tablets
EP1813275A1 (en) * 2005-12-20 2007-08-01 Teva Pharmaceutical Industries Ltd Lansoprazole orally disintegrating tablets
WO2007071420A1 (en) * 2005-12-23 2007-06-28 Lek Pharmaceuticals D.D. Bursting pellets
WO2007100984A2 (en) * 2006-02-24 2007-09-07 Allergan, Inc. Beads containing pyridin-sulfinyl benzoimidazole sulfonyl phenoxy acetate derivatives
CA2648278C (en) * 2006-04-03 2019-05-28 Isa Odidi Drug delivery composition
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
US8703191B2 (en) 2006-07-25 2014-04-22 Intelgenx Corp. Controlled-release pharmaceutical tablets
US7674479B2 (en) * 2006-07-25 2010-03-09 Intelgenx Corp. Sustained-release bupropion and bupropion/mecamylamine tablets
EP1894561A1 (en) * 2006-08-30 2008-03-05 Dr. Reddy's Laboratories Ltd. Dipyridamole pharmaceutical compositions
US20100105738A1 (en) * 2006-10-06 2010-04-29 Mitsuru Mizuno Extended release formulations of a proton pump inhibitor
KR20090090316A (en) 2006-11-09 2009-08-25 오렉시젠 세러퓨틱스 인크. Unit dosage package and methods for administering weight loss medications
JP2010509367A (en) 2006-11-09 2010-03-25 オレキシジェン・セラピューティクス・インコーポレーテッド Laminated formulation
CN101219118B (en) * 2007-01-08 2011-05-25 天津药物研究院 Impulse released oral medication preparation
WO2008094877A2 (en) * 2007-01-30 2008-08-07 Drugtech Corporation Compositions for oral delivery of pharmaceuticals
WO2009113090A2 (en) * 2008-01-17 2009-09-17 Alkem Laboratories Ltd. Process for preparing an oral formulation of an acid-sensitive benzimidazole drug
PE20091620A1 (en) 2008-03-11 2009-11-12 Takeda Pharmaceutical SOLID ORAL DISINTEGRATION PREPARATION
TWI519322B (en) 2008-04-15 2016-02-01 愛戴爾製藥股份有限公司 Compositions comprising weakly basic drugs and controlled-release dosage forms
WO2009158114A1 (en) 2008-05-30 2009-12-30 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
GB2460915B (en) * 2008-06-16 2011-05-25 Biovascular Inc Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor
SI22806A (en) * 2008-06-23 2009-12-31 Krka, Tovarna Zdravil, D.D., Novo Mesto New crystalline forms of sodium rabeprazole
US8282957B2 (en) * 2008-06-26 2012-10-09 Mcneil-Ppc, Inc. Coated particles containing pharmaceutically active agents
WO2010018175A2 (en) * 2008-08-11 2010-02-18 Mepha Ag Oral pharmaceutical formulation for omeprazole comprising a specific separation layer
EP2331084A4 (en) * 2008-10-06 2014-01-22 Jubilant Life Sciences Ltd Pharmaceutical compositions comprising amorphous esomeprazole, dosage forms and process thereof
US20110177164A1 (en) * 2008-10-06 2011-07-21 Gopal Rajan Pharmaceutical Compositions Comprising Amorphous Esomeprazole, Dosage Forms And Process Thereof
FR2938431B1 (en) 2008-11-14 2013-12-20 Debregeas Et Associes Pharma NOVEL COMPOSITION BASED ON GAMMA-HYDROXYBUTYRIC ACID
US20100189791A1 (en) * 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline malate formulation
FR2949061B1 (en) 2009-08-12 2013-04-19 Debregeas Et Associes Pharma FLOATING MICROGRANULES
FR2949062B1 (en) * 2009-08-12 2011-09-02 Debregeas Et Associes Pharma NEW PHARMACEUTICAL FORMULATIONS AGAINST MEASURING MEDICINES
US20110136815A1 (en) 2009-12-08 2011-06-09 Horst Zerbe Solid oral film dosage forms and methods for making same
US10610528B2 (en) 2009-12-08 2020-04-07 Intelgenx Corp. Solid oral film dosage forms and methods for making same
EP2345408A3 (en) * 2010-01-08 2012-02-29 Dr. Reddy's Laboratories Ltd. Acid labile drug formulations
AU2011203867B2 (en) 2010-01-11 2015-12-03 Nalpropion Pharmaceuticals Llc Methods of providing weight loss therapy in patients with major depression
EP2566466A1 (en) * 2010-05-03 2013-03-13 Aptalis Pharma Limited Micropellet compositions comprising pancreatin containing digestive enzyme mixtures
WO2011140446A2 (en) * 2010-05-06 2011-11-10 Dr. Reddy's Laboratories Ltd. Pharmaceutical formulations
MX2013000827A (en) * 2010-07-22 2013-06-28 Lupin Ltd Multiple unit tablet composition.
CN102475689B (en) * 2010-11-30 2015-04-01 杭州赛利药物研究所有限公司 Suspension dispersible tablets and preparation method
JP2014501224A (en) * 2010-12-27 2014-01-20 武田薬品工業株式会社 Orally disintegrating tablets
US10154964B2 (en) * 2011-09-07 2018-12-18 Cosmo Technologies Limited Controlled release and taste masking oral pharmaceutical composition
EP2659881B1 (en) * 2012-04-30 2017-11-29 Tillotts Pharma Ag A delayed release drug formulation
KR20210012056A (en) 2012-06-06 2021-02-02 오렉시젠 세러퓨틱스 인크. Methods of treating overweight and obesity
WO2014134049A1 (en) * 2013-03-01 2014-09-04 Bpsi Holdings, Llc. Delayed release film coatings containing calcium silicate and substrates coated therewith
CN104095850B (en) * 2013-04-03 2019-04-05 深圳信立泰药业股份有限公司 A kind of stable Pitavastatin calcium medicine compound and preparation method thereof
EP3288556A4 (en) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
CN104873471B (en) * 2015-06-12 2018-04-20 山东罗欣药业集团股份有限公司 A kind of RABEPRAZOLE SODIUM plain piece and sodium rabeprazole enteric-coated tablet
JP2017214341A (en) * 2016-06-01 2017-12-07 ニプロ株式会社 Oral pharmaceutical formulation
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
KR102006777B1 (en) * 2018-01-29 2019-10-08 주식회사 종근당 Pharmaceutical formulation comprising esomeprazole and sodium bicarbonate
KR102080023B1 (en) 2018-01-29 2020-02-21 주식회사 종근당 Stable pharmaceutical composition comprising esomeprazole and sodium bicarbonate
CN111789808A (en) * 2019-04-08 2020-10-20 生达化学制药股份有限公司 Oral pharmaceutical composition and structure thereof
CN112834627B (en) * 2019-11-22 2022-05-20 扬子江药业集团有限公司 Method for separating and measuring lansoprazole related substances for injection by high performance liquid chromatography
US20230000780A1 (en) 2019-12-11 2023-01-05 Evonik Operations Gmbh Dosage form comprising an alkaline agent and an enteric coating layer
US20230048354A1 (en) 2019-12-11 2023-02-16 Evonik Operations Gmbh Dosage form for use in treating or preventing of a disease
ES2975442T3 (en) 2019-12-11 2024-07-05 Evonik Operations Gmbh Pharmaceutical form for use in the treatment or prevention of a disease
KR20220065997A (en) * 2020-11-13 2022-05-23 (주)휴온스 Pharmaceutical combination preparation comprising rabeprazole and antacid and method for preparing the same

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
WO1994002140A1 (en) * 1992-07-17 1994-02-03 Astra Aktiebolag Pharmaceutical composition containing antiulcer agent
WO1998019668A1 (en) * 1996-11-06 1998-05-14 Sharmatek, Inc. Delayed delivery system for acid-sensitive drugs
WO1999048498A1 (en) * 1998-03-20 1999-09-30 A/S Gea Farmaceutisk Fabrik Pharmaceutical formulation comprising a 2- [[(2- pyridinyl) methyl] sulfinyl] benzimidazole having anti-ulcer activity and a process for the preparation of such formulation
WO2000012064A1 (en) * 1998-08-28 2000-03-09 Andrx Pharmaceuticals, Inc. Omeprazole formulation
WO2001041734A2 (en) * 1999-12-09 2001-06-14 Ratiopharm Gmbh Stable galenic preparations comprising a benzimidazol and method for the production thereof
US6346269B1 (en) * 2000-05-08 2002-02-12 Standard Chem. & Pharm. Co., Ltd. Method for preparing an oral formulation containing acid-sensitive drugs and oral formulation made thereby

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL75400A (en) * 1984-06-16 1988-10-31 Byk Gulden Lomberg Chem Fab Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same
JPS6150978A (en) * 1984-08-16 1986-03-13 Takeda Chem Ind Ltd Pyridine derivative and preparation thereof
US5433959A (en) * 1986-02-13 1995-07-18 Takeda Chemical Industries, Ltd. Stabilized pharmaceutical composition
CA1327010C (en) * 1986-02-13 1994-02-15 Tadashi Makino Stabilized solid pharmaceutical composition containing antiulcer benzimidazole compound and its production
GB2189699A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
US5026560A (en) * 1987-01-29 1991-06-25 Takeda Chemical Industries, Ltd. Spherical granules having core and their production
JPH01319944A (en) * 1988-06-21 1989-12-26 Mitsubishi Electric Corp Method and apparatus for forming thin film on surface of semiconductor substrate
FR2692146B1 (en) * 1992-06-16 1995-06-02 Ethypharm Sa Stable compositions of gastro-protected omeprazole microgranules and process for obtaining them.
ES2094694B1 (en) * 1995-02-01 1997-12-16 Esteve Quimica Sa NEW PHARMACEUTICALLY STABLE FORMULATION OF A COMPOUND OF BENZMIDAZOLE AND ITS PROCESS OF OBTAINING.
US6489346B1 (en) * 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US20010053387A1 (en) * 1997-05-23 2001-12-20 Hamied Yusuf Khwaja Benzimidazole pharmaceutical composition and process of prepatation
US6349269B1 (en) * 1998-12-11 2002-02-19 Dell U.S.A., L.P. Thermal management data prediction system
PT1108425E (en) * 1999-12-16 2005-10-31 Medinfar Produtos Farmaceutico NEW MULTI-MUNICIPAL PHARMACEUTICAL PREPARATIONS CONTAINING SUBSTITUTED BENZIMIDAZOES
US6437652B1 (en) * 2000-12-29 2002-08-20 Broadcom Corporation Apparatus and method for reducing phase noise in oscillator circuits
WO2004014345A1 (en) * 2002-08-02 2004-02-19 Ratiopharm Gmbh Pharmaceutical preparation containing a benzimidazole compound mixed with microcrystalline cellulose and a method for its preparation
ES2234393B2 (en) * 2003-04-29 2006-09-01 Laboratorios Belmac, S.A. "FORMULATIONS OF PELETS OF ANTIULCEROSE BENCIMIDAZOLIC COMPOUNDS AND LABILS TO THE ACID".

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
WO1994002140A1 (en) * 1992-07-17 1994-02-03 Astra Aktiebolag Pharmaceutical composition containing antiulcer agent
WO1998019668A1 (en) * 1996-11-06 1998-05-14 Sharmatek, Inc. Delayed delivery system for acid-sensitive drugs
WO1999048498A1 (en) * 1998-03-20 1999-09-30 A/S Gea Farmaceutisk Fabrik Pharmaceutical formulation comprising a 2- [[(2- pyridinyl) methyl] sulfinyl] benzimidazole having anti-ulcer activity and a process for the preparation of such formulation
WO2000012064A1 (en) * 1998-08-28 2000-03-09 Andrx Pharmaceuticals, Inc. Omeprazole formulation
WO2001041734A2 (en) * 1999-12-09 2001-06-14 Ratiopharm Gmbh Stable galenic preparations comprising a benzimidazol and method for the production thereof
US6346269B1 (en) * 2000-05-08 2002-02-12 Standard Chem. & Pharm. Co., Ltd. Method for preparing an oral formulation containing acid-sensitive drugs and oral formulation made thereby

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "Stabilized pharmaceutical composition", IP.COM, 17 September 2002 (2002-09-17), pages 1 - 2, XP002374253, Retrieved from the Internet <URL:https://priorart.ip.com/download/IPCOM000009757D/IPCOM000009757D.pdf> [retrieved on 20060325] *

Also Published As

Publication number Publication date
WO2005092297A2 (en) 2005-10-06
IL177869A0 (en) 2006-12-31
EP1720527A2 (en) 2006-11-15
CN1964704A (en) 2007-05-16
CA2558535A1 (en) 2005-10-06
US20050214372A1 (en) 2005-09-29
US20050214371A1 (en) 2005-09-29
JP2007526319A (en) 2007-09-13
MXPA06009991A (en) 2007-04-10

Similar Documents

Publication Publication Date Title
WO2005092297A3 (en) A stable pharmaceutical composition comprising an acid labile drug
UA88509C2 (en) Sublingual coated tablet comprising opioid analgesic
WO2006035417A3 (en) Dihydropyrimidine microcapsule - formulations
WO2008062440A3 (en) Programmable buoyant delivery technology
NO20073073L (en) Pharmaceutical preparation comprising an antibiotic, a triazole and a corticosteroid
WO2007034503A3 (en) Controlled release dosage formulation of duloxetine
SI1465608T1 (en) Extended release compositions comprising as active compound venlafaxine hydrochloride
WO2007103557A3 (en) Coating capsules with active pharmaceutical ingredients
WO2006044202A3 (en) Enteric coated compositions that release active ingredient(s) in gastric fluid and intestinal fluid
HK1096399A1 (en) P-glycoprotein inhibitor, method for preparing the same and pharmaceutical composition comprising the same p-
WO2005044240A3 (en) Stable lansoprazole formulation
WO2008022932A3 (en) Controlled release system and method for manufacturing the same
WO2007056073A3 (en) Medical device with a coating comprising an active form and an inactive form of therapeutic agent(s)
WO2005027843A3 (en) Chronotherapeutic dosage forms
MX341015B (en) Extended-release dosage form.
WO2006123364A3 (en) Oral drug delivery system providing a coating comprising both a cellulose and a methacrylic acid derivative
WO2009052516A3 (en) Method of coating medical devices
WO2005009410A3 (en) Pharmaceutical compositions having a swellable coating
WO2005039481A3 (en) Oral drug delivery system
WO2005117895A8 (en) Compositions comprising meloxicam
WO2007009691A3 (en) Combination of substituted pyrazolines and anti -addictive agent
EP1584335A3 (en) Active substance combination comprising a carbinol composition and an opioid
WO2010018175A3 (en) Oral pharmaceutical formulation for omeprazole comprising a specific separation layer
WO2003096874A3 (en) Coated sustained release tablets of a hygroscopic compound for once-a-day therapy
WO2004066982A8 (en) Stable oral benzimidazole compositions and processes for their preparation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: PA/a/2006/009991

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2005724184

Country of ref document: EP

Ref document number: 2007501900

Country of ref document: JP

Ref document number: 2558535

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 177869

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 5096/DELNP/2006

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 200580013417.0

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2005724184

Country of ref document: EP